A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

"REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% After FDA Response Letter -- BFA Law Announces Securities Fraud Investigation And Urges Investors To Contact The Firm >REPL" was published ...

Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Bitmine Immersion Stock Sheds Another 20% After $2B ATM Offering The company may sell up to $2 billion in stock through Cantor Fitzgerald and ThinkEquity in flexible at-the-market deals, according ...

Tesla shares tumbled after CEO Elon Musk announced that he plans to start a new political party, reigniting concerns that his attention will turn away from running the EV maker and that a public ...

While this opinion will undoubtedly be unpopular given the riches this company has bestowed on shareholders since 2023 began, there are seven valid reasons to believe Palantir stock can plunge 60% ...

Centene shares plummeted Wednesday after the managed-care company withdrew its full-year outlook after receiving new data about enrollments and rising member health costs. Monitor these major ...